TOLERABILITY OF ADJUNCTIVE LACOSAMIDE IN PAEDIATRIC PATIENTS AGED 4 TO <16 YEARS WITH FOCAL SEIZURES: AN INTERIM POOLED ANALYSIS OF DATA FROM OPEN-LABEL TRIALS

被引：0
|
作者：
Yuen, N. [1 ]
Taeter, C. [2 ]
Beller, C. [1 ]
Daniels, T. [1 ]
Bozorg, A. [1 ]
机构：
[1] UCB Pharma, Raleigh, NC USA
[2] UCB Pharma, Braine Lalleud, Belgium
来源：
EPILEPSIA | 2017年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
p0725
引用
收藏
页码：S132 / S132
页数：1
相关论文
共 50 条
  • [11] Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (aged 4 to <12 years) with inadequately controlled focal-onset seizures: Japanese subgroup analysis
    Omatsu, Hirowo
    Watanabe, Toshihide
    Kira, Ryutaro
    Ishiba, Kaeko
    Patten, Anna
    Takase, Takao
    Ngo, Leock Y.
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2023, 110 : 109 - 116
  • [12] Safety and Tolerability of Adjunctive Brivaracetam in Pediatric Patients < 16 Years with Epilepsy: An Open-Label Trial
    Edwin Liu
    Deanne Dilley
    Belinda McDonough
    Armel Stockis
    Tony Daniels
    Pediatric Drugs, 2019, 21 : 291 - 301
  • [13] Long-term Tolerability and Retention of Adjunctive Brivaracetam in Children With Primary Generalized or Mixed Seizure Types: Interim Subgroup Analysis of Pooled Data From two Open-label Trials
    Patel, Anup D.
    Gasalla, Teresa
    Nondonfaz, Xavier
    Elmoufti, Sami
    Elshoff, Jan-Peer
    NEUROLOGY, 2020, 94 (15)
  • [14] Safety And Tolerability Of Nintedanib In Patients With Ipf: Interim Analysis From An Open-Label Extension Of The Inpulsis® Trials (inpulsis®-On)
    Crestani, B.
    Ogura, T.
    Pelling, K.
    Quaresma, M.
    Coeck, C.
    Kaye, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [15] Evaluation of Long-Term Treatment with Lacosamide for Partial-Onset Seizures: A Pooled Analysis of Open-Label Extension Trials
    Rosenfeld, William
    Husain, Aatif
    Rosenow, Felix
    McShea, Cindy
    Isojarvi, Jouko
    Doty, Pamela
    NEUROLOGY, 2012, 78
  • [16] Safety and Tolerability of Adjunctive Eslicarbazepine Acetate in Pediatric Patients (Aged 4-17 Years) With Focal Seizures
    Mintz, Mark
    Pina-Garza, Jesus E.
    Wolf, Steven M.
    McGoldrick, Patricia E.
    Jozwiak, Sergiusz
    Grinnell, Todd
    Cantu, David
    Costa, Raquel
    Moreira, Joana
    Li, Yan
    Blum, David
    JOURNAL OF CHILD NEUROLOGY, 2020, 35 (04) : 265 - 273
  • [17] Adjunctive Levetiracetam in Patients Aged 1 Month to &lt;4 Years With Partial-Onset Seizures: Subpopulation Analysis of a Prospective, Open-Label Extension Study of up to 48 Weeks
    Pina-Garza, Jesus Eric
    Schiemann-Delgado, Jimmy
    Yang, Haichen
    Duncan, Benjamin
    Hadac, Jan
    Hunter, Scott J.
    CLINICAL THERAPEUTICS, 2010, 32 (11) : 1935 - 1950
  • [18] Interim Safety and Tolerability Analysis from an Open-label, Long-term Study of Adjunctive Brivaracetam in Pediatric Patients with Epilepsy
    Badalamenti, V
    Gasalla, T.
    Dilley, D.
    Dubois, F.
    Elshoff, J. P.
    ANNALS OF NEUROLOGY, 2017, 82 : S278 - S279
  • [19] Safety, tolerability, and efficacy of adjunctive lacosamide in pediatric patients with epilepsy syndromes associated with generalized seizures: Phase 2, open-label exploratory trial
    Auvin, Stephane
    Arzimanoglou, Alexis
    Beller, Cynthia
    Floricel, Florin
    Daniels, Tony
    Bozorg, Ali
    EPILEPSIA, 2023, 64 (11) : 2947 - 2957
  • [20] Efficacy and tolerability of a "Suprabioavailable" formulation of Fenofibrate in patients with dyslipidemia: A pooled analysis of two open-label trials
    Ramjattan, BR
    Callaghan, DJG
    Theiss, U
    CLINICAL THERAPEUTICS, 2002, 24 (07) : 1105 - 1116
12345